-
公开(公告)号：EP1716858B9
公开(公告)日：2009-08-12
申请号：EP05025974.6
申请日：2000-09-18
发明人： Bell, John Cameron , Sonenberg, Nahum , Stojdl, David Francis , Brown, Earl Garnet , Atkins, Harold Lawrence , Marius, Ricardo Marcellus , Lichty, Brian Dennis , Knowles, Shane Brendan
CPC分类号： C12N7/00 , A01K2267/0331 , A61K35/766 , A61K38/21 , C07K14/005 , C07K2319/00 , C07K2319/21 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20251 , C12N2760/20261 , A61K2300/00
摘要： The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
-
公开(公告)号：EP1716858B1
公开(公告)日：2008-12-24
申请号：EP05025974.6
申请日：2000-09-18
发明人： Bell, John Cameron , Sonenberg, Nahum , Stojdl, David Francis , Brown, Earl Garnet , Atkins, Harold Lawrence , Marius, Ricardo Marcellus , Lichty, Brian Dennis , Knowles, Shane Brendan
CPC分类号： C12N7/00 , A01K2267/0331 , A61K35/766 , A61K38/21 , C07K14/005 , C07K2319/00 , C07K2319/21 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20251 , C12N2760/20261 , A61K2300/00
摘要： The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
-
公开(公告)号：EP1716858A3
公开(公告)日：2007-08-15
申请号：EP05025974.6
申请日：2000-09-18
发明人： Bell, John Cameron , Sonenberg, Nahum , Stojdl, David Francis , Brown, Earl Garnet , Atkins, Harold Lawrence , Marius, Ricardo Marcellus , Lichty, Brian Dennis , Knowles, Shane Brendan
IPC分类号： A61K35/76
CPC分类号： C12N7/00 , A01K2267/0331 , A61K35/766 , A61K38/21 , C07K14/005 , C07K2319/00 , C07K2319/21 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20251 , C12N2760/20261 , A61K2300/00
摘要： The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
-
公开(公告)号：EP1716858A2
公开(公告)日：2006-11-02
申请号：EP05025974.6
申请日：2000-09-18
发明人： Bell, John Cameron , Sonenberg, Nahum , Stojdl, David Francis , Brown, Earl Garnet , Atkins, Harold Lawrence , Marius, Ricardo Marcellus , Lichty, Brian Dennis , Knowles, Shane Brendan
IPC分类号： A61K35/76
CPC分类号： C12N7/00 , A01K2267/0331 , A61K35/766 , A61K38/21 , C07K14/005 , C07K2319/00 , C07K2319/21 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20251 , C12N2760/20261 , A61K2300/00
摘要： The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
摘要翻译： 本发明涉及一种降低肿瘤细胞生存能力的方法，涉及向肿瘤细胞施用不是常见的人类病原体的病毒。 优选地，病毒表现出差异的易感性，因为正常细胞不受病毒的影响。 这种差异敏感性在干扰素存在下更显着。 肿瘤细胞的特征在于具有低水平或没有PKR活性，或PKR - / - ，STAT1 - / - 或PKR - / - 和 - STAT - / - 两者。 病毒选自由弹状病毒和小RNA病毒组成的组，优选为水泡性口炎病毒（VSV）或其衍生物。
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
